Neumora Therapeutics (NMRA) Receivables - Other (2022 - 2024)

Neumora Therapeutics' Receivables - Other history runs 3 years deep, the most recent figure standing at $1.6 million for Q2 2024.

• On a quarterly basis, Receivables - Other changed N/A year-over-year to $1.6 million in Q2 2024; TTM through Jun 2024 was $1.6 million, a N/A change from a year earlier, with the FY2023 full-year figure at $939000.0, up 2.18% from the prior year.
• Receivables - Other improved to $1.6 million in Q2 2024 per NMRA's latest filing, from $906000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $1.6 million in Q2 2024 and bottomed at $668000.0 in Q3 2023.
• The 3-year median for Receivables - Other is $919000.0 (2022), against an average of $1.0 million.
• Biggest YoY gain for Receivables - Other was 2.18% in 2023; the steepest drop was 2.18% in 2023.
• Year by year, Receivables - Other stood at $919000.0 in 2022, then climbed by 2.18% to $939000.0 in 2023, then soared by 73.7% to $1.6 million in 2024.
• Per Business Quant, the three latest NMRA Receivables - Other figures stand at $1.6 million (Q2 2024), $906000.0 (Q1 2024), and $939000.0 (Q4 2023).